2,4,7-Trichloropyrido[2,3-d]pyrimidine - CAS 938443-20-0
Catalog: |
BB057320 |
Product Name: |
2,4,7-Trichloropyrido[2,3-d]pyrimidine |
CAS: |
938443-20-0 |
Synonyms: |
2,4,7-Trichloropyrido[2,3-d]pyrimidine; 2,4,7-trichloro-pyrido[2,3-d]pyrimidine; Pyrido[2,3-d]pyriMidine,2,4,7-trichloro- |
IUPAC Name: | 2,4,7-trichloropyrido[2,3-d]pyrimidine |
Description: | 2,4,7-Trichloropyrido[2,3-d]pyrimidine is used in the synthetic preparation of dual mTORC1/mTORC2 inhibitors and the discovery of AZD8055 and AZD2014 as potential antitumor agents. |
Molecular Weight: | 234.47 |
Molecular Formula: | C7H2Cl3N3 |
Canonical SMILES: | C1=CC(=NC2=C1C(=NC(=N2)Cl)Cl)Cl |
InChI: | InChI=1S/C7H2Cl3N3/c8-4-2-1-3-5(9)12-7(10)13-6(3)11-4/h1-2H |
InChI Key: | DNFDLCRLLQVUQK-UHFFFAOYSA-N |
References: | Pike, K.G., et al. Bioorg. Med. Chem. Lett., 23, 1212 (2013). |
GHS Hazard Statement: | H301 (97.44%): Toxic if swallowed [Danger Acute toxicity, oral] |
Precautionary Statement: | P264, P264+P265, P270, P280, P301+P316, P305+P354+P338, P317, P321, P330, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
CN-113999226-A | Heterocyclic compounds as KRAS inhibitors and methods of use thereof | 20201222 |
WO-2021257736-A1 | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors | 20200618 |
WO-2021168193-A1 | Pyridopyrimidine derivatives as kras inhibitors | 20200220 |
WO-2021133509-A1 | Heterocyclic compounds as mtor inhibitors | 20191227 |
WO-2020224585-A1 | Salt and crystal form of mtorc1/2 dual kinase activity inhibitor and preparation method therefor | 20190506 |
WO-2020147842-A1 | Use of pyridopyrimidine compounds in preparation of drug for treating nasopharyngeal carcinoma | 20190118 |
US-2019336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | 20180501 |
WO-2019212990-A1 | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors | 20180501 |
WO-2019212991-A1 | C26-linked rapamycin analogs as mtor inhibitors | 20180501 |
AU-2019262978-A1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | 20180501 |
Complexity: | 192 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 232.93143 |
Formal Charge: | 0 |
Heavy Atom Count: | 13 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 0 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 232.93143 |
Rotatable Bond Count: | 0 |
Topological Polar Surface Area: | 38.7Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 3.7 |
-
Catalog: BB016398
4-chloro-6-methylimidazo[2,1-f][1,2,4]triazine
Detail
-
Catalog: BB012200
8-(tetramethyl-1,3,2-dioxaborolan-2-yl)-4H-chromen-4-one
Detail
-
Catalog: BB016397
1-methyl-3-(1,3-thiazol-2-yl)-1H-pyrazole-5-carbaldehyde
Detail
-
Catalog: BB054100
Azetidine
Detail
-
Catalog: BB006975
(3R)-N-methyloxolan-3-amine hydrochloride
Detail
-
Catalog: BB014781
1,4-Benzodioxane-6-carbonitrile
Detail
-
Catalog: BB002009
Ethylenesulfate
Detail
-
Catalog: BB016437
2-amino-3-{pyrrolo[2,1-f][1,2,4]triazin-5-yl}propanenitrile
Detail
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS